Gyre Therapeutics (NASDAQ:GYRE) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Gyre Therapeutics (NASDAQ:GYRE) issued its earnings results on Thursday. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.19, Zacks reports. Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. The company had revenue of $32.93 million during the quarter, compared to the consensus estimate of $28.40 million.

Gyre Therapeutics Stock Performance

Shares of GYRE stock traded up $0.75 on Friday, hitting $4.76. The stock had a trading volume of 359,716 shares, compared to its average volume of 149,986. The stock’s 50 day moving average is $6.51 and its 200-day moving average is $6.90. The firm has a market capitalization of $530.79 million, a price-to-earnings ratio of -23.80 and a beta of 2.14. Gyre Therapeutics has a 52-week low of $3.97 and a 52-week high of $9.14.

Analyst Ratings Changes

GYRE has been the topic of several analyst reports. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. Wall Street Zen raised Gyre Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Gyre Therapeutics in a report on Wednesday. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.